Open Access

Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD)

Respiratory Research201314:120

https://doi.org/10.1186/1465-9921-14-120

Received: 16 October 2013

Accepted: 5 November 2013

Published: 6 November 2013

Abstract

Small airway fibrosis is the main contributor to physiological airway dysfunction in COPD. One potential mechanism contributing to small airway fibrosis is epithelial mesenchymal transition (EMT). When associated with angiogenesis (so called EMT-Type-3) it may well also be the link with the development of cancer, which is closely associated with COPD and predominantly in large airways. In a recent study published in Respiratory Research, Qin Wang and colleagues investigated the role of urokinase plasminogen activator receptor (uPAR) in EMT in small airway epithelium of COPD patients. However, there are some issues with the paper which we wish to comment on.

Keywords

Epithelial mesenchymal transition Small airways Large airways COPD Lung cancer Vimentin

Letter to the Editor

Dear Editor

We read with interest the recent paper by Qin Wang and colleagues published in Respiratory Research (2013, 14:67, doi:10.1186/1465-9921-14-67), addressing epithelial mesenchymal transition (EMT) in COPD airways [1]. This is an important new area and it is quite reassuring that leading respiratory journals are now recognising the potential importance of EMT in pathogenesis of chronic obstructive pulmonary disease (COPD) and its deadly consequences. In this paper the authors conclude that increased urokinase plasminogen activator receptor (uPAR) expression in the small airway epithelium of patients with COPD is a manifestation of an active EMT process [1]. However, we have some issues with the paper.

Firstly, in the discussion Qin Wang and et al. questioned the relevance of our findings on active EMT in large airways of COPD patients. We agree that EMT-type-2 may be involved in pathogenesis of small airway and obliteration. However, a second major feature of COPD, namely, the striking vulnerability of early stage COPD to development of lung cancer [24], is also poorly understood. We have suggested that EMT-type-3 in larger airways provides an explanation [29]. Wang and et al. have missed this point in our paper, by being overly focused on EMT in small airways, EMT also seems to feature in idiopathic pulmonary fibrosis (IPF) and bronchiolitis obliterans syndrome (BOS) [211].

EMT when associated with increased angiogenesis of the reticular basement membrane (Rbm) and indeed epithelium itself (Figure 1), leads to the formation of a pro-cancer stroma (EMT-type-3) in contrast to mainly fibrosis-associated EMT-type-2 which lacks angiogenesis [24, 79, 12]. It is thought that this aberrant vessel plexus gives immune protection to developing malignant cells by preventing egress and local activity of natural killer (NK) cells [13, 14]. Fibroblasts originated from type-3 EMT are designated as “cancer-associated fibroblasts” [15]. This is well described in other epithelial malignancies [16]. It is of interest and relevance in this context that over 90% of human cancer arises in epithelia (e.g. breast, colon, stomach, liver, prostate, ovary/fallopian tube, bladder etc.), and the involvement of EMT in all of these may be a central paradigm [16]. It is pertinent that up to 70% of lung cancer occurs in the context of mild-to-moderate COPD [1719], and COPD-related cancer may well be just another example of this core principle of unstable epithelium in the context of tissue inflammation and/or chronic stimulation.
Figure 1

Airway tissue stained for type-IV collagen to highlight blood vessels. (A) Small airway section, black arrows indicating vessels in the lamina propria with no vessels in the Rbm or epithelium, typical of EMT Type-2; (B) bronchial biopsy section from a matched large airway, with black arrows indicating vessels with in Rbm and also penetrating into the epithelium, typical of EMT Type-3.

Our second major issue is the quality of immunostaining of small airway sections for EMT bio-markers in the Wang paper. In Figure 1A, the serial sections from COPD patients stained for E-cadherin (b) and vimentin (d) are not convincing. There is indeed decreased expression of E-cadherin in the epithelium but the authors failed to point out what other cells are staining for E-cadherin nearly 150 microns deep in the lamina propria (LP). If they have migrated from the epithelium they should have lost E-cadherin and should be positive for vimentin in the LP. This suggests some artefact; perhaps the authors should have considered double immunostaining for these markers. In addition, the non-smoker small airway tissue section demonstrates a quite hyperplastic appearance of the epithelium, suggesting aberrant phenotyping.

Finally, the authors show correlations between the expression of cell mesenchymal markers in small airways and lung function for all the 78 subjects together. However, this includes quite distinct groups, including normal, which are bound to give such a relationship. What is needed is an analysis of obstructed participants only, to see if greater expression of markers is related to increased loss of function. This seems unlikely from the data shown.

Inspite of our reservations, this is still an important study which highlights the potential of EMT to be central to COPD pathophysiology. Acceptance of this new concept will change the very way we think about this disease process and its nasty clinical consequences.

Abbreviations

BOS: 

Bronchiolitis obliterans syndrome

COPD: 

Chronic obstructive pulmonary disease

EMT: 

Epithelial mesenchymal transition

IPF: 

Idiopathic pulmonary fibrosis

LP: 

Lamina propria

NK: 

Natural killer cells

Rbm: 

Reticular basement membrane

uPAR: 

Urokinase plasminogen activator receptor

Declarations

Authors’ Affiliations

(1)
NHMRC Centre of Research Excellence for Chronic Respiratory Disease, School of Medicine, University of Tasmania
(2)
NHMRC Centre for Research Excellence in Chronic Respiratory Disease, School of Medicine, University of Tasmania

References

  1. Wang Q, Wang Y, Zhang Y, Xiao W: The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2013, 14: 67-10.1186/1465-9921-14-67.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Sohal SS, Walters EH: Epithelial mesenchymal transition (EMT) in small airways of COPD patients. Thorax. 2013, 68 (8): 783-784. 10.1136/thoraxjnl-2013-203373.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH: Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2013, 7 (3): 275-288. 10.1586/ers.13.26.PubMedView ArticleGoogle Scholar
  4. Sohal SS, Soltani A, Weston S, Wood-Baker R, Walters EH: Intermediate filament vimentin and potential role in epithelial mesenchymal transition (EMT). Vimentin Concepts and Molecular Mechanisms. Edited by: de Mello RA. 2013, New York: Nova Publishers, 37-62.Google Scholar
  5. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology. 2010, 15 (6): 930-938. 10.1111/j.1440-1843.2010.01808.x.PubMedView ArticleGoogle Scholar
  6. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011, 12 (1): 130-10.1186/1465-9921-12-130.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Soltani A, Muller HK, Sohal SS, Reid DW, Weston S, Wood-Baker R, Walters EH: Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology. 2012, 60 (6): 964-970. 10.1111/j.1365-2559.2011.04147.x.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Soltani A, Reid DW, Sohal SS, Wood-Baker R, Weston S, Muller HK, Walters EH: Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2010, 11 (1): 105-10.1186/1465-9921-11-105.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Soltani A, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH: Vessel-associated transforming growth factor-Beta1 (TGF-beta1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS One. 2012, 7 (6): e39736-10.1371/journal.pone.0039736.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Coward WR, Saini G, Jenkins G: The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2010, 4 (6): 367-388. 10.1177/1753465810379801.PubMedView ArticleGoogle Scholar
  11. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, Fisher AJ, Dark JH, Lordan JL, Kirby JA, et al: Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax. 2005, 60 (10): 865-871. 10.1136/thx.2005.043026.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119 (6): 1420-1428. 10.1172/JCI39104.PubMedPubMed CentralView ArticleGoogle Scholar
  13. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P: Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006, 12 (15): 4575-4582. 10.1158/1078-0432.CCR-06-0185.PubMedView ArticleGoogle Scholar
  14. Sarrazin SMC, Delmas D, Lassalle P, Delehedde M: Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther. 2010, 2 (2): 047-052. 10.4172/1948-5956.1000022.View ArticleGoogle Scholar
  15. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006, 6 (5): 392-401. 10.1038/nrc1877.PubMedView ArticleGoogle Scholar
  16. Garber K: Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J Natl Cancer Inst. 2008, 100 (4): 232-233. 10.1093/jnci/djn032. 239PubMedView ArticleGoogle Scholar
  17. Barnes PJ, Adcock IM: Chronic obstructive pulmonary disease and lung cancer: a lethal association. Am J Respir Crit Care Med. 2011, 184 (8): 866-867. 10.1164/rccm.201108-1436ED.PubMedView ArticleGoogle Scholar
  18. De Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Davila R, Zulueta JJ, Aguirre-Jaime A, Saetta M, et al: Lung cancer in patients with COPD: incidence and predicting factors. Am J Respir Crit Care Med. 2011, 184 (8): 913-919. 10.1164/rccm.201103-0430OC.PubMedView ArticleGoogle Scholar
  19. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD: COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009, 34 (2): 380-386. 10.1183/09031936.00144208.PubMedView ArticleGoogle Scholar

Copyright

© Sohal and Walters; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement